Navigation Links
New Osteoarthritis Research Grant Program Initiated by AOSSM and Genzyme Biosurgery
Date:2/25/2010

The American Orthopaedic Society for Sports Medicine (AOSSM), in partnership with Genzyme Biosurgery, is pleased to announce a new research grant program to fund investigations related to early osteoarthritis (OA) and/or prevention of OA progression.

Rosemont, IL (Vocus) February 25, 2010 -- The American Orthopaedic Society for Sports Medicine (AOSSM), in partnership with Genzyme Biosurgery, is pleased to announce a new research grant program to fund investigations related to early osteoarthritis (OA) and/or prevention of OA progression. This grant program reflects a growing recognition of the importance of osteoarthritis within the sports medicine and orthopaedics world. The program is an outgrowth of the Society’s conference on post-joint injury OA held in December 2008 and it underscores Genzyme’s long-standing commitment to osteoarthritis research and therapy.

“Genzyme is very pleased to continue our ongoing support of the AOSSM through this important research award. Our hope is that by providing greater opportunities to the orthopaedic sports medicine research community, more innovative ideas will be generated to help improve the lives of patients with this disabling disease,” said Jeffrey L Kraines, MD, Head, Medical Affairs and Senior Medical Director, Genzyme Biosurgery.

Two separate grants will be offered. One will provide an annual $50,000 grant for a clinical research study that is renewable for three years ($150,000 total), subject to a progress review. The second will be a one-time award of $50,000 to support a lab/basic science project to different investigators over a successive three year time period.

Proposed studies need not relate specifically to sports injuries and should also have broad applicability to OA in the general population. Projects involving viscosupplementation will not be considered for either grant. Applications will be reviewed for their potential impact on the field, the quality of study approach, and the ability of the investigator and site(s) to conduct and complete the proposed research.

The Principal Investigator on all applications must be an AOSSM member who has completed his or her training. It is expected that grantees will submit the results from their funded study to AOSSM for podium presentation and to the American Journal for Sports Medicine (AJSM) for publication. The submission deadline for both the clinical and basic science grants is August 1st, 2010. Award notices will be made on or after October 15th with a start date of January 1, 2011. Inquires can be directed to Bart Mann, AOSSM Director of Research (bart(at)aossm(dot)org). Additional information and application materials can be obtained on the AOSSM website at http://www.sportsmed.org/tabs/research/aossmgrants.aspx.

The American Orthopaedic Society for Sports Medicine (AOSSM) is a world leader in sports medicine education, research, communication and fellowship, and includes national and international orthopaedic sports medicine leaders. The Society works closely with many other sports medicine specialists, including athletic trainers, physical therapists, family physicians, and others to improve the identification, prevention, treatment, and rehabilitation of sports injuries. For more information, please contact AOSSM Director of Communications, Lisa Weisenberger, at 847/292-4900. Additional information and press releases can be viewed in the newsroom on AOSSM’s Web site at www.sportsmed.org. For more information about Genzyme Biosurgery, visit www.genzyme.com

# # #

Read the full story at http://www.prweb.com/releases/osteoarthritis/sports_medicine/prweb3650094.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Using coxibs and NSAIDs to treat osteoarthritis
2. Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis
3. New insights into inflammation in osteoarthritis
4. Study shows pine bark naturally reduces osteoarthritis knee pain
5. Orthopedic Surgeon Contributes Knowledge on Research and Treatment in Weekly Blogs on MyOsteoarthritisCentral.com
6. The risk of osteoarthritis and index to ring finger length ratio
7. Genes Linked to Height Also Tied to Osteoarthritis Risk
8. Gender Bias at Play in Treatment of Knee Osteoarthritis
9. Gender bias may affect care of people with osteoarthritis, study finds
10. Study Shows Pine Bark Naturally Reduces Osteoarthritis
11. Study shows pine bark naturally reduces osteoarthritis
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Osteoarthritis Research Grant Program Initiated by AOSSM and Genzyme Biosurgery 
(Date:10/13/2017)... (PRWEB) , ... October 13, ... ... School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, ... professionals on guideline updates for the primary prevention of cardiovascular diseases during ...
(Date:10/13/2017)... OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... or dementia. However, many long-term care insurance companies have a waiver for care if ... the 90-day elimination period, when the family pays for care, is often waived, so ...
(Date:10/13/2017)... ... ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many kids ... sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids excited ... all ages; it is a non-competitive, non-timed event, which is all about having fun ...
(Date:10/13/2017)... ... 13, 2017 , ... Coveros, a leader in agile coaching ... contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile ... of Agile methodologies in a consistent and high value manner across CMS programs. ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), an ... showcase a range of technology and learning solutions at the 68th Annual American ... to be held October 14–18, 2017 at the Mandalay Bay Resort in Las ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
(Date:9/19/2017)... HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that ... developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and ...
(Date:9/18/2017)... R.I. , Sept. 18, 2017 /PRNewswire/ ... the fields of bioinformatics and immune engineering, ... a protective avian influenza A (H7N9) vaccine. ... distantly related to seasonal influenza and presents ... rely on prior exposure to be effective. ...
Breaking Medicine Technology: